Encompass Health price target raised to $74 from $69 at BofA

BofA raised the firm’s price target on Encompass Health to $74 from $69 and keeps a Buy rating on the shares. The firm attributes guidance being raised by less than the Q1 beat to "typical EHC conservatism," while calling out noting Encompass’ business as "one of the most recession resistant in our coverage given its high acuity and senior patient base."